Post lumbar puncture syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:30:38 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Post lumbar puncture syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing Sphenopalatine Block Using Lidocaine and Prilocaine to Blood Patch for Patients with Post-Dural Puncture Syndrome https://clinicaltrials.eu/trial/comparing-sphenopalatine-block-using-lidocaine-and-prilocaine-to-blood-patch-for-patients-with-post-dural-puncture-syndrome/ Wed, 29 Apr 2026 15:07:50 +0000 https://clinicaltrials.eu/trial/comparing-sphenopalatine-block-using-lidocaine-and-prilocaine-to-blood-patch-for-patients-with-post-dural-puncture-syndrome/ This study examines post-dural puncture syndrome, a condition that occurs when a needle puncture through the protective membrane surrounding the spinal cord causes fluid to leak, leading to severe headaches that worsen when sitting or standing upright. The study will compare two treatment approaches: a sphenopalatine block and a blood patch. The sphenopalatine block involves applying numbing medication through the nose using either XYLOCARD, which contains anhydrous lidocaine hydrochloride, or EMLA cream, which contains both lidocaine and prilocaine. The blood patch is the current standard treatment where a small amount of the patient’s own blood is injected near the site of the original puncture to seal the leak. The purpose of the study is to evaluate whether the sphenopalatine block is as effective as the blood patch in managing headaches caused by post-dural puncture syndrome within seven days of treatment.

Patients participating in this study will have experienced persistent headaches for at least 24 hours despite receiving conservative treatment such as rest, fluids, and pain medication. They will receive either the sphenopalatine block or the blood patch procedure. After the treatment, headache intensity will be measured using a scale from zero to ten, where zero means no pain and ten represents the worst possible pain. These measurements will be taken at multiple time points: at the start of the procedure, then at 30 minutes, one hour, two hours, six hours, 24 hours, 48 hours, and seven days after treatment. The treatment period lasts one day, with follow-up assessments continuing for seven days.

The study will also track several other aspects of patient care and recovery. This includes monitoring how much pain medication patients need after the procedure, whether additional treatment with a blood patch becomes necessary, and how long patients need to stay in the hospital during the seven-day period following treatment. Any unwanted effects that occur during the procedure will be recorded, as well as any serious complications. Patient satisfaction with the treatment will be assessed seven days after the procedure using a rating scale. The study aims to determine whether the sphenopalatine block offers a comparable alternative to the blood patch for managing this painful condition.

]]>